Haptoglobin 2-2 phenotype is associated with decreased ferroxidase activity in smokers

被引:7
作者
Awadallah, SM [1 ]
机构
[1] Hashemite Univ, Dept Med Technol, Zarqa 13133, Jordan
关键词
haptoglobin; smokers; cardiovascular diseases; ferroxiclase; lipid profile; Jordan;
D O I
10.1016/S0009-8981(03)00164-5
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Back-g-round: Cigarette smoking and the inheritance of Hp 2-2 phenotype have been separately linked to cardiovascular disease. In this study, the combined effects of smoking and the presence of Hp 2-2 type on predisposition to cardiovascular disease were investigated. Methods: Fasting blood specimens were collected from 489 Jordanian males (228 smokers and 261 nonsmokers). Haptoglobin phenotype was determined by electrophoresis, and lipid profile and ferroxidase activity were determined by spectrophotometric methods. Results: The results show that, irrespective of Hp type, total- and LDL-cholesterol levels were significantly higher in smokers compared with nonsmokers, while levels of HDL-cholesterol and ferroxidase activity were lower in smokers. There was no significant difference between the three Hp types in nonsmokers regarding the lipid profile and ferroxidase activity. In the smokers group, however, serum ferroxidase activity was significantly lower in individuals with Hp 2-2 type compared with that in Hp 1-1 and Hp 2-1 smoker individuals. Smokers with the Hp 2-2 type have significantly higher levels of total- and LDL-cholesterol and lower HDL-cholesterol levels compared with that in nonsmokers expressing the same Hp type. Conclusion: These findings demonstrate that smokers with Hp 2-2 phenotype have a decreased antioxidant capacity suggesting that smoking coupled with the inheritance of an Hp-2-2 type predispose to more oxidative stress and cardiovascular disease. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:71 / 76
页数:6
相关论文
共 38 条
[1]  
AGIL A, 1995, CLIN CHEM, V41, P220
[2]  
Awadallah S, 2000, CYTOBIOS, V101, P145
[3]   Associations between haptoglobin polymorphism, lipids, lipoproteins and inflammatory variables [J].
Braeckman, L ;
De Bacquer, D ;
Delanghe, J ;
Claeys, L ;
De Backer, G .
ATHEROSCLEROSIS, 1999, 143 (02) :383-388
[4]   OXIDATION-RELATED ANALYTES AND LIPID AND LIPOPROTEIN CONCENTRATIONS IN HEALTHY-SUBJECTS [J].
CRAIG, WY ;
POULIN, SE ;
PALOMAKI, GE ;
NEVEUX, LM ;
RITCHIE, RF ;
LEDUE, TB .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (06) :733-739
[5]   CIGARETTE-SMOKING AND SERUM-LIPID AND LIPOPROTEIN CONCENTRATIONS - AN ANALYSIS OF PUBLISHED DATA [J].
CRAIG, WY ;
PALOMAKI, GE ;
HADDOW, JE .
BMJ-BRITISH MEDICAL JOURNAL, 1989, 298 (6676) :784-788
[6]   Smoking, lipoproteins and coronary heart disease risk - Data from the Munster Heart Study (PROCAM) [J].
Cullen, P ;
Schulte, H ;
Assmann, G .
EUROPEAN HEART JOURNAL, 1998, 19 (11) :1632-1641
[7]   Effect of smoking on ceruloplasmin and its ferroxidase activity in pregnant women [J].
Dalamaga, AL ;
Agroyannis, B ;
Vitoratos, N ;
FrangosPlemenos, M ;
Patsouras, K ;
KostoglouPapalamprou, M ;
Zourlas, PA .
GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1996, 42 (01) :13-15
[8]   Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery [J].
Delanghe, J ;
Cambier, B ;
Langlois, M ;
DeBuyzere, M ;
Neels, H ;
DeBacquer, D ;
VanCauwelaert, P .
ATHEROSCLEROSIS, 1997, 132 (02) :215-219
[9]   Haptoglobin polymorphism and peripheral arterial occlusive disease [J].
Delanghe, J ;
Langlois, M ;
Duprez, D ;
De Buyzere, M ;
Clement, D .
ATHEROSCLEROSIS, 1999, 145 (02) :287-292
[10]  
Delanghe J R, 1995, J Cardiovasc Risk, V2, P131, DOI 10.1097/00043798-199504000-00008